Establishment of the 'DKU-HANMI Innovative New Drug Research Center' at Dankook University
Han Kwan-soon, Vice Chairman of Hanmi Pharmaceutical (third from the left in the front row), and Kim Soo-bok, President of Dankook University (third from the right in the front row), are taking a commemorative photo with officials after the agreement ceremony on the 10th. (Photo by Hanmi Pharmaceutical)
[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical is partnering with Dankook University to jointly research next-generation resistant lung cancer targeted innovative new drugs.
Hanmi Pharmaceutical and Dankook University announced on the 11th that they held a joint research agreement ceremony and the opening ceremony of the joint research center at Dankook University Cheonan Campus Industry-Academic Cooperation Hall on the 10th. The ceremony was attended by key figures from both sides, including Lee Kwan-soon, Vice Chairman of Hanmi Pharmaceutical, and Kim Soo-bok, President of Dankook University.
Under this agreement, Hanmi Pharmaceutical will develop innovative anticancer drugs that overcome lung cancer resistance with fewer side effects and superior efficacy, based on the lung cancer resistance mechanism research and new target discovery technology conducted by Professor Cho Jeong-hee of the Department of Biomedical Engineering at Dankook University. To accelerate this project, Hanmi Pharmaceutical established the ‘DKU-HANMI Innovative New Drug Research Center’ equipped with the latest research facilities within Dankook University.
Professor Cho has conducted tumor genomics and large-scale functional genomics-based screening research for over 15 years at institutions including Harvard Medical School’s Dana-Farber Cancer Institute. Currently, Professor Cho’s laboratory receives research support under the ‘Basic Research Laboratory Support Project’ from the Ministry of Science and ICT and the National Research Foundation of Korea.
Furthermore, Hanmi Pharmaceutical and Dankook University plan to collaborate on human resource exchanges for various clinical trials, academic and educational activities, utilization of research and development facilities, and sharing infrastructure to establish an industry-academic cooperation foundation.
Vice Chairman Lee said, "Hanmi Pharmaceutical continuously secures future competitiveness through an open innovation strategy that actively utilizes promising internal and external resources. This collaboration is expected to be an innovative case that maximizes Hanmi’s accumulated know-how and capabilities in anticancer drug development to create synergy between industry and academia."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
